熱門資訊> 正文
Lexaria Bioscience因350万美元股票发行而暴跌
2025-12-15 21:59
- Lexaria Bioscience (LEXX) announced a registered direct offering to sell about 2.66 million shares at $1.315 per share, raising gross proceeds of roughly $3.5 million.
- The company will also issue unregistered warrants to buy an additional 2.66 million shares at an exercise price of $1.19, exercisable immediately and expiring five years after the related resale registration becomes effective.
- Closing date is December 16, 2025.
- The aggregate gross proceeds of $3.5M will be used to advance its research and development efforts, fund working capital and for other general corporate purposes.
- LEXX -26.1% premarket to $0.99
- Source: Press Release
More on Lexaria Bioscience Corp.
- Lexaria Bioscience announces ~$4M registered direct offering of shares
- Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading
- Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp.
- Historical earnings data for Lexaria Bioscience Corp.
- Financial information for Lexaria Bioscience Corp.
推薦文章
年終盤點 | 最賺錢打新榜出爐！一手最高賺1.46萬，首日狂飆超360%，2025港股打新到底有多猛？
美股機會日報 | 貴金屬史詩級牛市！黃金年內飆升70%，漲破4500美元關口；英特爾遭利空一度跌逾5%
聖誕節休市提醒：港股休市兩天半，美股休市一天半
谷歌年初在人工智能競賽中落后，卻在2025年末登頂行業榜首
華盛早報 | 美聯儲主席熱門人選哈塞特：降息節奏仍需加速！英偉達稱春節前向中國交付H200芯片；中芯國際對部分產能漲價10%
12月24日外盤頭條：美國消費者信心連續第五個月下滑 金銀連續兩日刷新歷史新高 特朗普提美聯儲主席必要條件
美聯儲主席候選人哈塞特：美國在降息方面已嚴重滯后
資金覆盤 | 北水淨買入港股6.11億港元，加倉阿里超13億港元，賣出騰訊超10億港元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
